This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alexion's (ALXN) Soliris' Label Expansion Approved in Europe
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) announced that the European Commission (EC) approved a label expansion of lead drug Soliris which should further boost sales.
Why Regeneron Pharmaceuticals, Inc. (REGN) Might Be a Diamond in the Rough
by Zacks Equity Research
Investors might have overlooked the Zacks #1 Rank Regeneron Pharmaceuticals, Inc. (REGN) stock that has seen solid estimate revision in past one month but that is not reflected in its price performance.
Pfizer's (PFE) Besponsa Gets FDA Nod with a Boxed Warning
by Zacks Equity Research
Pfizer, Inc.'s (PFE) leukemia candidate, Besponsa received FDA approval, though with a boxed warning on the label.
Seattle Genetics' Adcetris Granted Priority Review by FDA
by Zacks Equity Research
Seattle Genetics, Inc.'s (SGEN) supplemental Biologics License Application for Adcetris in patients with cutaneous T-cell lymphoma has been accepted by the FDA and granted priority review.
Novo Nordisk's Semaglutide Shows Remarkable Results in Study
by Zacks Equity Research
Novo Nordisk (NVO) pipeline candidate shows superior glucose control and weight loss in study in diabetes patients compared with Eli Lilly and Co's Trulicity (dulaglutide).
Regeneron's (REGN) RSV Drug Suptavumab Fails NURSERY Trial
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) announced disappointing results from a phase III study, NURSERY Pre-term on suptavumab .
Spectrum (SPPI) Initiates Phase II Study for Cancer Drug
by Zacks Equity Research
Spectrum Pharmaceuticals, Inc. (SPPI) initiated the registrational phase III study of qapzola in patients with non-muscle invasive bladder cancer (NMIBC) as per the FDA's requirement.
Ophthotech's Fovista Combo Regimen Disappoints in Phase III
by Zacks Equity Research
Ophthotech (OPHT) disappoints with poor evaluation of Fovista combined with Eylea or Avastin for treatment of AMD in phase III. The study misses the primary endpoint.
Biotech Stock Roundup: Regeneron Drops RSV Antibody, Gilead HIV Drug Gets Priority Review
by Arpita Dutt
This week, companies like Regeneron (REGN) and Ionis provided updates on their pipeline while Gilead announced priority review for its HIV drug.
Regeneron vs. Alexion: Which Stock is a Better Pick Post Q2 Earnings?
by Arpita Dutt
Biotech companies, Regeneron (REGN) and Alexion, both topped estimates in Q2 and raised their outlook. But, which stock is better-positioned for the second half of the year?
Forget Teva (TEVA), Buy These 4 Drug Stocks Instead
by Arpita Dutt
With generic drugmakers like Teva (TEVA) under pressure, here is a look at four drug stocks that look well-positioned.
Puma (PBYI) Q2 Loss Narrower than Expected, Nerlynx in Focus
by Zacks Equity Research
Puma Biotechnology (PBYI) reported narrower-than-expected loss in Q2. Shares were down in after-hours trading.
Geron (GERN) Q2 Loss Narrows, Sales Miss Estimates, Stock Up
by Zacks Equity Research
Geron Corporation (GERN) reported narrower-than-expected loss in Q2 while sales missed estimates. Shares were up in after-hours trading.
Inovio (INO) Q2 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Inovio Pharmaceuticals (INO) reports narrower-than-expected loss with revenue beating estimates. Moreover, the top line significantly increases year over year.
Biotech Stock Roundup: Q2 Earnings from Regeneron, Kite & More, FibroGen Up on IPF Data
by Arpita Dutt
Regeneron (REGN) and several other biotech companies reported Q2 earnings while FibroGen hit a 52-week high on promising idiopathic pulmonary fibrosis (IPF) data.
The Zacks Analyst Blog Highlights: ExxonMobil, MasterCard, Shell, Regeneron and BP
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ExxonMobil, MasterCard, Shell, Regeneron and BP
Top Research Reports for ExxonMobil, MasterCard & Shell
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including ExxonMobil (XOM), MasterCard (MA), and Shell (RDS.A).
Regeneron (REGN) Beats on Q2 Earnings & Sales, Raises View
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) reported strong second-quarter results wherein both earnings and sales beat expectations on the back of Eylea sales.
Regeneron (REGN) Q2 Earnings Beat Estimates
by Ekta Bagri
Regeneron Pharmaceuticals (REGN) reported second quarter results, beating estimates on both counts
What's in the Cards for Adverum (ADVM) this Earnings Season?
by Zacks Equity Research
Investors will be looking at Adverum's (ADVM) updates on progress of its various pipeline candidates.
Sanofi (SNY) Q2 Earnings In Line, Sales Lag,'17 View Raised
by Zacks Equity Research
Sanofi (SNY) Q2 results were mixed as it reported in-line earnings and slightly missed sales expectations. However, the company raised its 2017 earnings guidance.
Ophthotech (OPHT) Q2 Loss Narrows, Focus Shifts to Zimura
by Zacks Equity Research
Ophthotech Corporation (OPHT) reported narrower-than-expected loss in the second quarter and also beat sales expectations.
Can Regeneron Pharma (REGN) Pull a Surprise in Q2 Earnings?
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release second-quarter 2017 results on Aug 3 and we expect focus on Eylea's performance.
5 Top Multibagger Biotech Stocks to Buy in the 2nd Half
by Tirthankar Chakraborty
Draconian crackdown on drug prices easing out and likelihood of a series of buyouts will help innovation starved biotech companies to gain in the second half.
Sanofi Versus AstraZeneca: Large Cap Pharma Stock Faceoff
by Zacks Equity Research
Both stocks carry a Zacks Rank #2 (Buy).